Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube Lubrication (SHG vs LC)

18 novembre 2026 mis à jour par: Yi Duan, Beijing Tsinghua Chang Gung Hospital

Superiority of Sodium Hyaluronate Gel Over Lidocaine Cream for Endotracheal Tube Lubrication in Reducing Postoperative Throat Numbness: A Randomized Controlled Trial

This study is a prospective, randomized, single-blind, parallel-group, single-center clinical trial in adults undergoing elective laparoscopic surgery under general anesthesia with endotracheal intubation. It will compare sterile medical sodium hyaluronate gel with lidocaine cream as a lubricant applied to the distal portion and cuff surface of the endotracheal tube. The study aims to evaluate whether sodium hyaluronate gel is superior to lidocaine cream in reducing postoperative throat numbness. The primary outcome is throat numbness assessed using a visual analog scale (VAS) 30 minutes after surgery. Secondary outcomes include throat numbness at other specified time points, coughing during emergence and after the first oral water intake, postoperative sore throat, hoarseness, endotracheal tube cuff pressure, hemodynamic responses during intubation and extubation, satisfaction, and adverse events. A total of 120 participants are planned, with 60 participants in each group.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

120

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18 to 65 years, of either sex.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Patients scheduled for elective laparoscopic surgery under general anesthesia with endotracheal intubation.
  • Expected surgical duration of 1 to 4 hours.
  • Able to understand the study and provide written informed consent.

Exclusion Criteria:

  • Patients expected to be transferred to the intensive care unit (ICU) postoperatively.
  • Known or anticipated difficult airway.
  • History of severe respiratory disease, such as asthma or chronic obstructive pulmonary disease.
  • High risk of gastroesophageal reflux or aspiration, including a full stomach or a history of severe gastroesophageal reflux disease.
  • Known allergy to sodium hyaluronate, lidocaine, or any other study-related medication/product.
  • Pre-existing sore throat or hoarseness before surgery.
  • Pregnancy or breastfeeding.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Medical sodium hyaluronate lubricating gel

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. The protocol lists medical device registration certificate number

Comparateur actif: Lidocaine cream

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Throat numbness intensity
Délai: 30 minutes after extubation

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

30 minutes after extubation

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Throat numbness intensity
Délai: Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.
Time to first oral water intake and incidence of coughing during the first water intake
Délai: From extubation to the first oral water intake, within 24 hours after extubation.

The time from extubation to the first oral water intake will be recorded in minutes. The occurrence of coughing during the first water intake will also be recorded.

From extubation to the first oral water intake, within 24 hours after extubation.
Severity of coughing during emergence from general anesthesia
Délai: During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.

Coughing during emergence and extubation will be graded as follows: 0 = no cough; 1 = mild, single cough; 2 = moderate, more than one cough with a duration of less than 5 seconds; 3 = severe, cough lasting more than 5 seconds. Suctioning during emergence will be recorded. No routine suctioning will be performed at extubation or during the first 5 minutes after extubation, unless clinically required.

During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.
Postoperative sore throat severity
Délai: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative sore throat severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no sore throat, whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe sore throat.

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Postoperative hoarseness severity
Délai: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative hoarseness severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no hoarseness , whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe hoarseness .

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Endotracheal tube cuff pressure measured in cmH₂O
Délai: At 1, 2, and 3 hours after intubation, and immediately before extubation.

Endotracheal tube cuff pressure will be measured using a cuff pressure manometer. The pressure will be recorded in cmH₂O.

At 1, 2, and 3 hours after intubation, and immediately before extubation.
Incidence of hemodynamic abnormalities assessed by heart rate and blood pressure measurements
Délai: During tracheal extubation

Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) will be monitored and recorded. Hemodynamic abnormalities are defined as HR greater than 100 beats/min or less than 60 beats/min; SBP ≥140 mmHg and/or DBP ≥90 mmHg; or a decrease in SBP of more than 20% from baseline.

During tracheal extubation
Anesthesiologists' satisfaction with the assigned endotracheal tube lubricant
Délai: Immediately after tracheal intubation.

Anesthesiologists' satisfaction with the assigned lubricant will be evaluated using a 5-point Likert scale, with scores ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.

Immediately after tracheal intubation.
Patient satisfaction with the anesthesia recovery process
Délai: Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.

Patient satisfaction with the anesthesia recovery process will be assessed using a 5-point Likert scale during the PACU stay. Scores range from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction.

Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.
Incidence of adverse events associated with the study interventions
Délai: From administration of the assigned lubricant until 24 hours after extubation.

The occurrence of adverse events, including allergic reactions, laryngospasm, aspiration, nausea, and vomiting, will be recorded and compared between the two groups.

From administration of the assigned lubricant until 24 hours after extubation.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

4 novembre 2026

Achèvement primaire (Estimé)

4 mars 2027

Achèvement de l'étude (Estimé)

10 mars 2027

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

18 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner